ScholarIQanswers from OpenAlex & ORCID
Martin R. Farlow
ResearcherPublications, citations & collaboration network
Martin R. Farlow is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Martin R. Farlow have?
ScholarIQindexed works
Martin R. Farlow has 805 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Martin R. Farlow have?
ScholarIQcitation count
Martin R. Farlow has 62,964 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Martin R. Farlow?
ScholarIQh-index
Martin R. Farlow has an h-index of 117 in OpenAlex.
What is the i10-index of Martin R. Farlow?
ScholarIQi10-index
Martin R. Farlow has an i10-index of 451 in OpenAlex.
What is the ORCID of Martin R. Farlow?
ScholarIQorcid
The ORCID for Martin R. Farlow is on the source record.
What is the OpenAlex record for Martin R. Farlow?
ScholarIQopenalex
The OpenAlex for Martin R. Farlow is on the source record.
What are the most-cited papers on Martin R. Farlow?
ScholarIQmost cited works
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
Adam C. Naj, Gyungah Jun, Gary W. Beecham, Li‐San Wang, Badri N. Vardarajan, Jacqueline L. Buros, Paul J. Gallins, Joseph D. Buxbaum, Gail P. Jarvik, Paul K. Crane, Eric B. Larson, Thomas D. Bird, Bradley F. Boeve, Neill R. Graff‐Radford, Philip L. De Jager, Denis A. Evans, Julie A. Schneider, Minerva M. Carrasquillo, Nilüfer Ertekin‐Taner, Steven G. Younkin, Carlos Cruchaga, John Kauwe, Petra Nowotny, Patricia Kramer, John Hardy, Matthew J. Huentelman, Amanda Myers, M. Michael Barmada, F. Yesim Demirci, Clinton T. Baldwin, Robert C. Green, Ekaterina Rogaeva, Peter St George‐Hyslop, Steven E. Arnold, Robert C. Barber, Thomas G. Beach, Eileen H. Bigio, James D. Bowen, Adam Boxer, James R. Burke, Nigel J. Cairns, Chris Carlson, Regina M. Carney, Steven L. Carroll, Helena C. Chui, David G. Clark, Jason J. Corneveaux, Carl W. Cotman, Jeffrey L. Cummings, Charles DeCarli, Steven T. DeKosky, Ramon Diaz‐Arrastia, Malcolm Dick, Dennis W. Dickson, William G. Ellis, Kelley M. Faber, Kenneth B. Fallon, Martin R. Farlow, Steven H. Ferris, Matthew P. Frosch, Douglas Galasko, Mary Ganguli, Marla Gearing, Daniel H. Geschwind, Bernardino Ghetti, John R. Gilbert, Sid Gilman, Bruno Giordani, Jonathan D. Glass, John H. Growdon, Ronald L. Hamilton, Lindy E. Harrell, Elizabeth Head, Lawrence S. Honig, Christine M. Hulette, Bradley T. Hyman, Gregory A. Jicha, Lee‐Way Jin, Nancy Johnson, Jason Karlawish, Anna Karydas, Jeffrey Kaye, Ronald Kim, Edward H. Koo, Neil W. Kowall, James J. Lah, Allan I. Levey, Andrew P. Lieberman, Oscar L. López, Wendy J. Mack, Daniel Marson, Frank Martiniuk, Deborah C. Mash, Eliezer Masliah, Wayne C. McCormick, Susan M. McCurry, Andrew McDavid, Ann C. McKee, Marsel Mesulam, Bruce L. Miller
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Harald Hampel, M.‐Marsel Mesulam, A. Claudio Cuello, Martin R. Farlow, Ezio Giacobini, George T. Grossberg, Ara S. Khachaturian, Andrea Vergallo, Enrica Cavedo, Peter J. Snyder, Zaven S. Khachaturian
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow, Takeshi Iwatsubo, Bruno Vellas, Steven Joffe, Karl Kieburtz, Rema Raman, Xiaoying Sun, Paul Aisen, Eric Siemers, Hong Liu‐Seifert, Richard C. Mohs
Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil
Pierre N. Tariot, Martin R. Farlow, George T. Grossberg, Stephen M. Graham, Scott A. McDonald, I. Gergel, for the Memantine Study Group
Estrogen for Alzheimer’s disease in women
Victor W. Henderson, Annlia Paganini‐Hill, Bruce L. Miller, Rodger J. Elble, P. F. Reyes, Donna Shoupe, Carol McCleary, Raymond Klein, Ann Marie Hake, Martin R. Farlow